Pharma major Bharat Biotech’s Covid-19 vaccine, Covaxin, is being administered through an injection in the country’s inoculation drive.
Now, the company has received a nod from India’s drug regulator to conduct phase 2 and 3 clinical trials of their against COVID-19.
The Department of Biotechnology said on Friday that early-stage trials of the vaccine candidate, BBV154, have been completed in subjects aged 18 to 60 years
“No serious adverse events reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit a high level of neutralizing antibodies in animal studies,” the release said.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. Bharat Biotech has in-licensed technology from Washington University in St Louis, USA.